Allen C Gao

Summary

Affiliation: University of California
Country: USA

Publications

  1. Nadiminty N, Tummala R, Liu C, Lou W, Evans C, Gao A. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther. 2015;14:1884-95 pubmed publisher
    ..These findings may provide a rationale for cotargeting these pathways to achieve better efficacy through AR blockade. ..
  2. Qu S, Wang K, Xue H, Wang Y, Wu R, Liu C, et al. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014;8:311-22 pubmed publisher
    ..Our findings, obtained with a highly clinically relevant prostate cancer model, suggest, for the first time, that docetaxel-based therapy of advanced human prostate cancer may be improved by combining docetaxel with Aneustat. ..
  3. Liu C, Lou W, Zhu Y, Yang J, Nadiminty N, Gaikwad N, et al. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015;75:1413-22 pubmed publisher
  4. Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao A. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clin Cancer Res. 2015;21:4133-42 pubmed publisher
    ..These studies may lead to the development of combinational therapies with bicalutamide/enzalutamide and docetaxel as effective regimens to treat advanced prostate cancer independent of AR status, and possibly other types of cancer. ..
  5. Gao A, Zhu Y. Stat5a/b in Prostate Cancer Metastasis. Am J Pathol. 2015;185:2351-3 pubmed publisher
    ..This commentary highlights the article by Talati et al that describes novel mechanisms promoting metastasis in prostate cancer. ..
  6. Lombard A, Liu L, Cucchiara V, Liu C, Armstrong C, Zhao R, et al. Intra vs Inter Cross-Resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018;: pubmed publisher
    ..Additionally, the development and use of biomarkers indicating resistance will improve patient stratification for treatment. ..
  7. Liu C, Armstrong C, Lou W, Lombard A, Evans C, Gao A. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017;16:35-44 pubmed publisher
    ..Mol Cancer Ther; 16(1); 35-44. ©2016 AACR. ..
  8. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans C, et al. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 2013;12:1829-36 pubmed publisher
  9. Chandrasekar T, Yang J, Gao A, Evans C. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015;13:206 pubmed publisher
    ..We review current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes. ..

More Information

Publications13

  1. Armstrong C, Gao A. CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer. J Cell Commun Signal. 2017;11:89-91 pubmed publisher
    ..The data from this manuscript highlight an intriguing potential therapeutic target for the treatment of CRPC and are a critical step forwards towards treating enzalutamide resistant prostate cancer. ..
  2. Cucchiara V, Yang J, Mirone V, Gao A, Rosenfeld M, Evans C. Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel). 2017;9: pubmed publisher
  3. Liu C, Armstrong C, Lou W, Lombard A, Cucchiara V, Gu X, et al. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017;16:1521-1530 pubmed publisher
    ..i>Mol Cancer Ther; 16(8); 1521-30. ©2017 AACR. ..
  4. Lombard A, Liu C, Armstrong C, Cucchiara V, Gu X, Lou W, et al. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2017;16:2257-2266 pubmed publisher
    ..Furthermore, these preclinical studies suggest the potential in using combinations of antiandrogens with cabazitaxel for increased effect in treating advanced CRPC. Mol Cancer Ther; 16(10); 2257-66. ©2017 AACR. ..